Clinical Trials Logo

Citation(s)

BMS CA180-097: A Phase II Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer, Previously Treated With Chemotherapy

Details for clinical trial NCT00570700